natural killer cell Archives -

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to

Gilead dives deeper into NK cell therapies with Dragonfly deal

https://pharmaphorum.com/news/gilead-dives-deeper-into-nk-cells-with-dragonfly-deal/

Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13

AACR: Affimed builds case for natural killer cell therapy

https://pharmaphorum.com/news/aacr-affimed-builds-case-for-natural-killer-cell-therapy/

Gilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging

Gilead combs Shoreline for NK cell therapies in $2.3bn alliance

https://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/

natural killer cell